Publications

British journal of cancer

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

14-06-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

01-06-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

15-05-2004

European journal of cancer (Oxford, England : 1990)

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

01-05-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

01-04-2004

Investigational new drugs

Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

01-04-2004

Journal of pharmacokinetics and pharmacodynamics

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

01-04-2004

Journal of mass spectrometry : JMS

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.

01-04-2004

Journal of mass spectrometry : JMS

Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

01-03-2004

Journal of mass spectrometry : JMS

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-03-2004

Cancer chemotherapy and pharmacology

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

01-02-2004

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.

30-01-2004

Analytical biochemistry

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

01-01-2004

Journal of chromatography. A

Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.

12-12-2003

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

05-12-2003

British journal of cancer

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

03-11-2003

Cancer research

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

01-10-2003

Drug development and industrial pharmacy

Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.

01-10-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

01-09-2003

Anti-cancer drugs

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

01-08-2003

PDA journal of pharmaceutical science and technology

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

25-07-2003

Laboratory animals

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

01-07-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

01-07-2003

Anti-cancer drugs

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

01-07-2003

Therapeutic drug monitoring

Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.

01-06-2003

The Journal of biological chemistry

Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.

16-05-2003

Journal of mass spectrometry : JMS

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

01-05-2003

Investigational new drugs

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

01-05-2003

Anti-cancer drugs

Metabolism of paclitaxel in mice.

01-03-2003

Journal of pharmaceutical and biomedical analysis

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

26-02-2003

Therapeutic drug monitoring

High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.

01-02-2003

Annals of oncology : official journal of the European Society for Medical Oncology

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

01-02-2003

The Journal of pharmacology and experimental therapeutics

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

01-02-2003

Biochemical pharmacology

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

15-01-2003

The oncologist

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

20-12-2002

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.

01-12-2002

Cancer treatment reviews

DNA-based drug interactions of cisplatin.

01-12-2002

Cancer chemotherapy and pharmacology

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.

01-12-2002

Molecular pharmacology

Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.

01-12-2002

Proceedings of the National Academy of Sciences of the United States of America

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.

26-11-2002

AIDS (London, England)

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

22-11-2002

Journal of pharmaceutical and biomedical analysis

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.

07-11-2002

International journal of pharmaceutics

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

06-11-2002

International journal of pharmaceutics

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

06-11-2002

British journal of clinical pharmacology

Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).

01-11-2002

Anti-cancer drugs

E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.

01-11-2002

Bone marrow transplantation

Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.

01-11-2002

Cancer research

Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.

01-11-2002

Anti-cancer drugs

Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.

01-10-2002

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.

01-10-2002